Glofitamab in Real Life
The Lymphoma Academic Research Organisation
250 participants
Dec 1, 2025
OBSERVATIONAL
Conditions
Summary
To date, more than 300 patients have been treated with Glofitamab in the Expanded Access Programme (EAP) in France. In this study, it is proposed to perform a retrospective analysis of some of these patients. The aim is to describe the efficacy and safety of Glofitamab in the largest reported real-world cohort, with an expected median follow-up of more than 9 months. Particular focus will be given to the relapsed or refractory chimeric antigen receptors-T (CAR-T) population to confirm the response rates (CRR: 35-39%) of Glofitamab in this population and to assess the optimal timing of therapy initiation \[8, 15\].
Eligibility
Inclusion Criteria4
- patient enrolled in the French Glofitamab EAP for R/R DLBCL before 2024 November 1st, 2024
- patient who received at least Obinutuzumab pretreatment and one infusion of Glofitamab
- adult patient
- patient who is informed of the study and who did not oppose to their data collection
Exclusion Criteria1
- none
Interventions
Glofitamab received for DLBCL in Early Phase Access
Locations(30)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06994169